Rare diseases, affecting 400 million people worldwide, present unique challenges in drug development. With over 7,000 rare diseases affecting more than 30 million people in the United States alone, the need for effective treatments is immense. Despite advancements since the Orphan Drug Act of 1983, most rare diseases still lack FDA-approved treatments. Here’s how you can accelerate your orphan drug development for rare diseases:

An image representing a rare disease

Pre-formulation and API Characterization

The journey begins with a thorough understanding of the active pharmaceutical ingredient (API). This involves studying its physical and chemical properties, stability, and solubility. The insights gained at this stage lay the foundation for the formulation development.

Formulation and Process Development

Next, we develop a formulation that ensures the orphan drug is delivered effectively. This involves selecting the right excipients and creating a manufacturing process that ensures the quality and consistency of the drug product.

First-in-human Clinical Testing and Acceleration into POC Trials

The first-in-human (FIH) clinical testing is a critical milestone in orphan drug development. It’s the first time the drug is tested in humans, providing valuable information about the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics. We can help accelerate this process into Proof of Concept (POC) trials, providing early-stage data to guide further development of the drug candidate.

Clinical Trial Manufacturing and Supply

Renejix provides bespoke clinical trial manufacturing and supply services, ensuring that the orphan drug product is available for Phase I-III patient trials. This includes manufacturing the drug product in the required quantities and packaging it appropriately for distribution to clinical trial sites.

Rapid Scale-up and Commercial Manufacturing

Once the orphan drug candidate has proven to be safe and effective, the we can rapidly scale up the manufacturing process and begin commercial production. This ensures that once regulatory approval is obtained, the drug can be quickly made available to patients suffering from the rare disease.

Related Services

Image of a Tablet
Learn More
Medicine in a spoon
Learn More
Semi-solid medicine
Learn More
Image showing Plus sign in a metallic film
Learn More
Image showing Plus sign in Medicine
Learn More

Related Content

FAQs

Here are some frequently asked questions about Orphan Disease / Rare Disease
.

What is an Orphan Disease, and how does Renejix support its treatment?

An Orphan Disease is a condition that affects a small percentage of the population. Renejix is committed to supporting the development and manufacturing of treatments for these rare diseases by providing specialized CDMO services that cater to the unique needs of Orphan Drug development.

Can you describe the range of CDMO services Renejix offers for Orphan Drugs?

Renejix offers a comprehensive suite of CDMO services for Orphan Drugs, including drug formulation, process development, clinical trial materials manufacturing, and commercial-scale production. We work closely with our partners to bring these critical treatments to market.

How does Renejix ensure the quality and compliance of Orphan Drugs?

Quality assurance is a cornerstone of our services. Renejix ensures compliance with stringent industry standards, reducing risk and guaranteeing product integrity. Our state-of-the-art facilities and experienced team ensure that every product meets or exceeds the highest quality benchmarks.

What makes Renejix a preferred partner for Orphan Drug development?

Renejix is a preferred partner due to our deep expertise in small molecule oral dosage development, delivery technologies, and multi-modality manufacturing. We provide customized solutions and scalability, ensuring a faster time-to-market for Orphan Drugs.

How does Renejix handle the unique challenges of Orphan Drug development?

We address the challenges of Orphan Drug development by employing innovative techniques to increase bioavailability or achieve controlled release for challenging APIs. Our team is adept at developing new formulation approaches and optimizing existing products.

Can Renejix support global regulatory requirements for Orphan Drugs?

Absolutely. Renejix offers regulatory services to ensure global compliance, streamline approvals, and support the product lifecycle with strategic regulatory planning and quality assurance.

What technologies does Renejix utilize for Orphan Drug formulation development?

Renejix employs a range of oral technologies and integrated solutions to enhance efficacy, bioavailability, adherence, and safety. Our innovative techniques are dedicated to addressing the formulation challenges of poorly soluble drugs.

Does Renejix provide clinical manufacturing services for Orphan Drugs?

Yes, we do. Renejix’s comprehensive services encompass small, pilot, full-scale, and adaptive manufacturing solutions across all phases of clinical trials for Orphan Drugs.

How does partnering with Renejix benefit the development of Orphan Drugs?

Partnering with Renejix offers numerous benefits, including faster time-to-market, risk mitigation, and expert guidance throughout the development process. Our client-centric approach ensures that your project is handled with the utmost care and professionalism.